Diagnosis

Insulinoma

Beta cell neoplasm with overproduction of insulin.

Etiology

Cause [b9s]

Pathophysiology [b9s]

  1. Normal physiology: Declining blood glucose suppress insulin secretion to prevent hypoglycemia

  2. An insulin-secreting neuroendocrine tumor, deriving mainly from pancreatic islet cells

  3. Some insulinomas also secrete other hormones: gastrin, 5-hydroxyindolic acid, adrenocorticotropic hormone, glucagon, human chorionic gonadotropin, and somatostatin

  4. Genetic mutations/dysregulations in signaling pathways that govern cell proliferation and hormone secretion

  5. Pathophysiology: Loss of feedback inhibition --> Autonomous and unregulated secretion of insulin --> hyperinsulinemia --> hypoglycemia --> catecholamine release

Epidemiology

Incidence per 100.000 [1ad][tru][b9s]

Epidemiology chart for Incidence

Approach

Treatment

  1. Dietary modifications [1ad]

  2. Medication to avoid hypoglycemia: Diazoxide, octreotide, pasireotide

  3. Surgical resection with intraoperative ultrasound [b9s]

    • Enucleation: small (<2 cm) benign tumors

    • Distal pancreatectomy

    • Central pancreatectomy

    • Pancreaticoduodenectomy

  4. Malignant insulinoma:

    • Surgery: complete oncological resection and regional lymph nodes dissection

    • 80% of the patients have liver metastasis:

      • Hepatic resection

      • Hepatic artery embolization combined with doxorubicin or streptozotocin

      • Liver transplantation [hqr]

      • Unresectable/metastatic:

        • Everolimus/sunitinib (antiproliferative effect)

        • Chemotherapy (streptozotocin, doxorubicin, 5-FU, cisplatin, etoposide)

        • Somatostatin positive tumor: radionuclide therapy (yttrium/lutetium)

Differential diagnoses

Adrenal insufficiency, Glucagonoma, Munchausen syndrome, Wermer syndrome


References

[1] Zhuo F, Menon G, Anastasopoulou C. Insulinoma. [Updated 2025 Jan 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544299/

[2] Cigrovski Berkovic M, Ulamec M, Marinovic S, Balen I, Mrzljak A. Malignant insulinoma: Can we predict the long-term outcomes? World J Clin Cases. 2022 Jun 6;10(16):5124-5132.

[3] Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the Patient: Insulinoma. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109-1118.

[4] https://www.uptodate.com/contents/insulinoma

[5] http://emedicine.medscape.com/article/283039 (2014-01-02); [Medscape]

[6] https://highervasc.co.uk/wp-content/uploads/2022/03/PDF22.pdf

[7] Zhao Y, Yu J, Liu Y, Lyu L, Ping F, Xu L, Li W, Wang O, Xu Q, Wu W, Zhang H, Li Y. Analysis of 55 patients with multiple endocrine neoplasia type 1-associated insulinoma from a single center in China. Orphanet J Rare Dis. 2022 Jun 13;17(1):219.

Scroll to top